{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:19:20Z","timestamp":1778591960580,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","transplantation-proceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.transproceed.2017.02.046","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T15:15:17Z","timestamp":1503674117000},"page":"1560-1564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report"],"prefix":"10.1016","volume":"49","author":[{"given":"I.A.","family":"Echenique","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ramirez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.02.046_bib1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.02.046_bib2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.02.046_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcv.2011.12.019","article-title":"Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis","volume":"53","author":"Boivin","year":"2012","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.transproceed.2017.02.046_bib4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/TP.0b013e3181fdd9d2","article-title":"Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis","volume":"90","author":"Chou","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.02.046_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study","volume":"18","author":"Young","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.02.046_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/342385","article-title":"Ganciclovir-resistant cytomegalovirus in organ transplant recipients","volume":"35","author":"Limaye","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.transproceed.2017.02.046_bib10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.02.046_bib11","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.00836-08","article-title":"Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir","volume":"53","author":"Perrottet","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.transproceed.2017.02.046_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.transproceed.2017.02.046_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/cid\/cit211","article-title":"Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence","volume":"57","author":"Muldoon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?","volume":"26","author":"Scott","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.transproceed.2017.02.046_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2017.02.046_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s11255-012-0293-y","article-title":"The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation","volume":"45","author":"Bedino","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.transproceed.2017.02.046_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/tid.12317","article-title":"Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients","volume":"16","author":"Gagermeier","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/tid.12133","article-title":"Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation","volume":"15","author":"Posadas Salas","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.02.046_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/petr.12179","article-title":"New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients","volume":"18","author":"\u00c5sberg","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2017.02.046_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1399-0012.2001.150501.x","article-title":"Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection","volume":"15","author":"Tornatore","year":"2001","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2017.02.046_bib21","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1001\/jama.1987.03390220080025","article-title":"Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts","volume":"257","author":"Erice","year":"1987","journal-title":"JAMA"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517303020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517303020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T05:08:57Z","timestamp":1535432937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517303020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0041134517303020"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.02.046","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.02.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}